Story Continues "I am thrilled about the progress to bring SYD-101 to market for the millions of pediatric patients impacted by this growing epidemic," said Professor Mark Bullimore, OD, Ph.D.

"The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study," said Patrick Johnson, Ph.D., President of Sydnexis.

Santen is Sydnexis' Licensing Partner to Commercialize SYD-101 within the EMEA Region upon issuance of a Marketing Authorization by the European Commission Sydnexis, Inc. (www.sydnexis.com), a pre ...

Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjuneain the European Union Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company ...